LEADER 03536nam 2200637Ia 450 001 9910462082103321 005 20200520144314.0 010 $a1-283-63636-0 010 $a0-309-25316-0 035 $a(CKB)2670000000275075 035 $a(EBL)3379028 035 $a(SSID)ssj0000665821 035 $a(PQKBManifestationID)11396035 035 $a(PQKBTitleCode)TC0000665821 035 $a(PQKBWorkID)10646588 035 $a(PQKB)10153786 035 $a(MiAaPQ)EBC3379028 035 $a(Au-PeEL)EBL3379028 035 $a(CaPaEBR)ebr10606369 035 $a(CaONFJC)MIL394882 035 $a(OCoLC)902942425 035 $a(EXLCZ)992670000000275075 100 $a20111220d2012 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aEnvisioning a transformed clinical trials enterprise in the United States$b[electronic resource] $eestablishing an agenda for 2020: workshop summary /$fNeil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs; Forum on Drug Discovery, Development, and Translation; Board on Health Sciences Policy 210 $aWashington $cNational Academies Press$d2012 215 $a1 online resource (232 p.) 300 $aDescription based upon print version of record. 311 $a0-309-25315-2 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Tables, Figures, and Boxes""; ""Acronyms""; ""1 Introduction""; ""2 Integrating Community Practice and Clinical Trials""; ""3 Improving Public Participation in Clinical Trials""; ""4 Creating a New Business Model for Clinical Trials""; ""5 Building an Infrastructure to Support Clinical Trials""; ""6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: Participant Biographies""; ""Appendix C: Registered Workshop Attendees"" 327 $a""Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation""""Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce""; ""Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials""; ""Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure""; ""Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research""; ""Appendix I: Discussion Paper: Health Research as a Public Good""; ""Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience"" 327 $a""Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise"" 606 $aClinical trials$zUnited States 606 $aClinical medicine$xResearch$zUnited States 608 $aElectronic books. 615 0$aClinical trials 615 0$aClinical medicine$xResearch 676 $a615.50724 701 $aWeisfeld$b Neil E$0897031 701 $aEnglish$b Rebecca A$0897032 701 $aClaiborne$b Anne B$0897033 712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation. 712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy. 712 02$aNational Academies Press (U.S.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910462082103321 996 $aEnvisioning a transformed clinical trials enterprise in the United States$92004268 997 $aUNINA LEADER 01265nam a2200325 i 4500 001 991000749389707536 005 20020507173104.0 008 990304s1997 de ||| | eng 020 $a3540627316 035 $ab10752006-39ule_inst 035 $aLE01301721$9ExL 040 $aDip.to Matematica$beng 082 0 $a515.352 084 $aAMS 58F12 084 $aAMS 58F13 084 $aAMS 58F14 100 1 $aPumarino, Antonio$061870 245 10$aCoexistence and persistence of strange attractors /$cAntonio Pumarino, J. Angel Rodríguez 260 $aBerlin :$bSpringer-Verlag,$cc1997 300 $aviii, 194 p. :$bill. ;$c24 cm. 490 0 $aLecture notes in mathematics,$x0075-8434 ;$v1658 500 $aIncludes bibliographical references (p. [193]-194) and index 650 4$aChaotic behavior in systems 700 1 $aRodriguez, J. Angel$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0441064 907 $a.b10752006$b23-02-17$c28-06-02 912 $a991000749389707536 945 $aLE013 58F PUM11 (1997)$g1$i2013000115870$lle013$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i10845057$z28-06-02 996 $aCoexistence and persistence of strange attractors$978844 997 $aUNISALENTO 998 $ale013$b01-01-99$cm$da $e-$feng$gde $h0$i1